NorthStar Medical Radioisotopes and Monopar Therapeutics have entered a partnership to develop a COVID-19 therapeutic drug that combines NorthStar-supplied therapeutic radioisotopes with Monopar's humanized urokinase plasminogen activator receptor-targeted monoclonal antibody that seeks to curb cytokine storms associated with COVID-19-related severe lung damage. "Our hope is that, by joining forces, we can develop a targeted radiopharmaceutical treatment that has the ability to prevent patients with severe COVID-19 from being placed on ventilators and from dying," said NorthStar CEO Stephen Merrick.
NorthStar, Monopar collaborate to develop COVID-19 drug
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.